News
Market and company headlines
ALGSAll
Loading
12:00Oct 51 Story
04:00-09:00Sep 212 Stories
Discover the top movers in Monday's pre-market session.
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
01:00Sep 211 Story
06:00-09:00Sep 22 Stories
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that members of management will present at the Cantor Global Healthcare Conference. Cantor Global Healthcare Conference Fireside Chat on Wednesday, September 9, 2026 at 8:00am ET The presentation will premiere at the time listed above
Aligos Therapeutics Shares Rise 7.6% Premarket Following Recent Company Updates
Aligos Therapeutics (NASDAQ:ALGS) shares rose 7. 6% to $6.
04:00Sep 21 Story
12:00Aug 121 Story
09:00-13:00Aug 102 Stories
Keep an eye on the top gainers and losers in Monday's session.
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Jin Medical International (NASDAQ:ZJYL) shares rose 58.1% to $3.4 during Monday's regular session. The market value of their outstanding shares is at $16.8 million. As per the press release, H1 earnings
04:00-09:00Aug 62 Stories
Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results
SOUTH SAN FRANCISCO, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today reported recent business progress and financial results for the second quarter 2026. “Our team has continued to execute on our key strategic priorities to advance our pipeline this year,” stated Lawrence Blatt, Ph.D., M.B.A., Chairman, Pres
Aligos Therapeutics Q2 EPS $(0.14) Beats $(1.07) Estimate, Sales $0.000 Miss $18.243M Estimate
Aligos Therapeutics (NASDAQ:ALGS) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(1.07) by 86.92 percent. This is a 90.85 percent increase over losses of $(1.53) per share